Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates

Snydman, David R.; Werner, Barbara G.; Meissner, Harald; Cheeseman, Sarah H.; Schwab, Jonathan; Bednarek, Francis J.; Kennedy, Joseph L.; Herschel, Marguerite; Magno, Andrea; Levin, Myron J.; Valaes, Timos; Berkman, Eugene M.; McIver, James; Leszczynski, Jeanne; Griffith, John; Grady, George F.

doi:10.1097/00006454-199501000-00007

Cited by 38 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinically, the passive administration of intravenous immunoglobulins containing high levels of HCMV antibodies (HCMV-specific hyperimmune globulin) can protect against disease in newborns, resulting from the infusion of HCMVcontaining blood (250), and can increase virus-specific immunoglobulin G concentrations and avidity and significantly lower the risk of congenital HCMV infection and disease in pregnant women (185). In the transplant setting, the importance of the humoral response is supported by the fact that HCMV infection is more frequent and severe in seronegative SOT recipients of an HCMV-positive organ (155).…”

Section: Immune-based Strategies For the Prevention And Treatment Of mentioning

confidence: 99%

Immunobiology of Human Cytomegalovirus: from Bench to Bedside

2009

View full text Add to dashboard Cite

SUMMARY Following primary infection, human cytomegalovirus (HCMV) establishes lifelong latency and periodically reactivates without causing symptoms in healthy individuals. In the absence of an adequate host-derived immune response, this fine balance of permitting viral reactivation without causing pathogenesis is disrupted, and HCMV can subsequently cause invasive disease and an array of damaging indirect immunological effects. Over the last decade, our knowledge of the immune response to HCMV infection in healthy virus carriers and diseased individuals has allowed us to translate these findings to develop better diagnostic tools and therapeutic strategies. The application of these emerging technologies in the clinical setting is likely to provide opportunities for better management of patients with HCMV-associated diseases.

show abstract

Section: Immune-based Strategies For the Prevention And Treatment Of mentioning

confidence: 99%

Immunobiology of Human Cytomegalovirus: from Bench to Bedside

2009

View full text Add to dashboard Cite

show abstract

“…Early studies have shown that passively acquired maternal anti-CMV antibodies protected against transfusion-associated CMV infection in the immediate postnatal period (61). Passive transfer of CMVspecific antibodies in multiply transfused preterm infants has also been shown to be protective in terms of the reduction of CMV disease (48). Although maternal seropositivity prior to pregnancy does not provide full protection against prenatal infection and disease (5), more recent studies have claimed that treatment of pregnant women with CMV-specific hyperimmune globulin was effective in prevention of congenital CMV infection (32).…”

Section: Human Cytomegalovirus (Hcmv) Is the Most Frequent Cause Of Cmentioning

confidence: 99%

Passive Immunization Reduces Murine Cytomegalovirus-Induced Brain Pathology in Newborn Mice

Cekinović

Golemac

Pugel

et al. 2008

J Virol

View full text Add to dashboard Cite

show abstract

“…The presence of transplacentally acquired antiviral antibodies has been demonstrated to modify the severity of HCMV disease in transfusion-associated HCMV infection in newborn infants (90). Passive transfer of antibodies has been shown to be effective in preventing disease in premature newborns and in solid-organ recipients (19,75,86). In addition, the presence of HCMVspecific antibodies prior to conception has been shown to correlate with decreased viral transmission and a reduction in the incidence of clinical manifestations in the child (23).…”

Section: Cytomegalovirus-specific Cd8mentioning

confidence: 99%

Dense Bodies of Human Cytomegalovirus Induce both Humoral and Cellular Immune Responses in the Absence of Viral Gene Expression

Pepperl

Münster

Mach

et al. 2000

J Virol

View full text Add to dashboard Cite

Infection of fibroblast cell cultures with human cytomegalovirus (HCMV) leads to the production of significant amounts of defective enveloped particles, termed dense bodies (DB). These noninfectious structures contain major antigenic determinants which are responsible for induction of both the humoral and the cellular immune response against HCMV. We tested the hypothesis that, by virtue of their unique antigenic and structural properties, DB could induce a significant immune response in the absence of infectious virus. Mice were immunized with gradient-purified DB, which were either left untreated or subjected to sequential rounds of sonication and freeze-thawing to prevent cellular entry. Titers of neutralizing antibodies induced by DB were in a range comparable to levels present in convalescent human sera. The virus-neutralizing antibody response was surprisingly durable, with neutralizing antibodies detected 12 months following primary immunization. The HCMV-specific major histocompatibility complex class I-restricted cytolytic T-cell (CTL) response was assayed using mice transgenic for the human HLA-A2 molecule. Immunization with DB led to high levels of HCMV-specific CTL in the absence of de novo viral protein synthesis. Maximal total cytolytic activity in mice immunized with DB was nearly as efficient as the cytolytic activity induced by a standard immunization with murine cytomegalovirus. Furthermore, DB induced a typical T-helper 1 (Th1)-dominated immune response in mice, as determined by cytokine and immunoglobulin G isotype analysis. Induction of humoral and cellular immune responses was achieved without the concomitant use of adjuvant. We thus propose that DB can serve as a basis for the future development of a recombinant nonreplicating vaccine against HCMV. Finally, such particles could be engineered for efficient delivery of antigens from other pathogens to the immune system.

show abstract

Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates

Cited by 38 publications

References 0 publications

Immunobiology of Human Cytomegalovirus: from Bench to Bedside

Immunobiology of Human Cytomegalovirus: from Bench to Bedside

Passive Immunization Reduces Murine Cytomegalovirus-Induced Brain Pathology in Newborn Mice

Dense Bodies of Human Cytomegalovirus Induce both Humoral and Cellular Immune Responses in the Absence of Viral Gene Expression

Contact Info

Product

Resources

About